AI Science Tracker

Biohub

1 discovery from 2026

Discoveries

AI-prioritized CRISPR screen identifies ALOX5 and OXTR as regulators of keratinocyte IL17RA in psoriasis

A genome-wide CRISPR knockout screen in primary human epidermal keratinocytes, combined with VirtualCRISPR language-model prioritization, identified ALOX5 and OXTR as previously underappreciated cell-intrinsic regulators of surface IL17RA. Targeted knockout in keratinocytes from two adult donors reduced IL17RA and inflammatory cytokine secretion. Topical inhibition of ALOX5 or OXTR also reduced disease signs in an imiquimod mouse model of psoriasiform dermatitis.

Technology: VirtualCRISPR, a functional-genomics language-model framework trained on BioGRID-ORCS screens

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: A genome-wide CRISPR knockout screen in primary human epidermal keratinocytes, combined with VirtualCRISPR language-model prioritization, identified ALOX5 and OXTR as previously underappreciated cell-intrinsic regulators of surface IL17RA.
  • Still unknown: The genetic validation used primary cells from two donors, while therapeutic effects were tested in an imiquimod-induced mouse model, not patients. The screen provided the initial unbiased hits; the AI supplied an orthogonal novelty-prioritization layer and did not itself measure biological effects. The paper reports a provisional patent application covering methods and findings. No clinical efficacy, safety or topical treatment benefit in humans is established.
  • AI role: After the unbiased genome-wide CRISPR screen, VirtualCRISPR scored whether perturbing each gene in primary adult keratinocytes would alter IL17RA expression. The authors combined screen enrichment with the model’s lower prior probability for noncanonical hits to prioritize high-novelty regulators; targeted CRISPR knockout and pharmacologic mouse experiments tested the resulting biology.

Evidence sources: https://www.nature.com/articles/s41467-026-75249-5

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.